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Abstract
Over the last year, significant steps have beenmade toward understanding the pathogenesis of esophageal
diseases and translating this knowledge to clinical practice. Gastroesophageal reflux disease (GERD) is the
most common outpatient diagnosis in gastroenterology and has a high prevalence in the general
population. Asmany as 40% of patients with GERDhave incomplete response tomedical therapy, and the
pathophysiological mechanisms underlying lack of response are now better understood. Novel medical
and minimally invasive interventions are available to optimize management of GERD. Esophageal cancer,
regardless of the histological subtype, has among the worst survival statistics among all malignancies.
Taking advantage of technological advances in genome sequencing, the mutational spectra in esophageal
cancer are now emerging, offering novel avenues for targeted therapies. Early diagnosis is another strand
for improving survival. While genome-wide association studies are providing insights into genetic
susceptibility, novel approaches to early detection of cancer are being devised through the use of
biomarkers applied to esophageal samples and as part of imaging technologies. Dysmotility and
eosinophilic esophagitis are the differential diagnoses in patients with dysphagia. New pathophysiological
classifications have improved the management of motility disorders. Meanwhile, exciting progress has
been made in the endoscopic management of these conditions. Eosinophilic esophagitis is still a relatively
new entity, and the pathogenesis remains poorly understood. However, it is now clear that an allergic
reaction to food plays an important role, and dietary interventions as well as biologic agents to block the
inflammatory cascade are novel, promising fields of clinical research.
Introduction
This review highlights research advances made over the
last year in esophageal diseases, with particular reference
to gastroesophageal reflux disease (GERD), premalig-
nant and malignant conditions, eosinophilic esophagitis
(EoE), and motility disorders. Understanding molecular
and pathophysiological mechanisms of disease is para-
mount to improve patient management. Recent techno-
logical advances have made it possible to uncover genetic
factors involved in the etiopathogenesis and progression
of disease, with the possibility to translate this into
improved identification of individuals at risk and
introduce molecular targeted therapies. This review will
focus on how molecular research can improve patient
care and on the most relevant recent clinical studies in
esophageal disease.
Gastroesophageal reflux disease
In the last 10 to 20 years, GERD has placed an enormous
burden on the Western world, and the prevalence in the
general population varies between 20% and 30% [1,2].
A recent analysis of a large US national database revealed
that GERD was the most common gastrointestinal (GI)
diagnosis in an outpatient setting, accounting for almost
9 million visits in 2009 [3]. Up to 70% of patients with
typical GERD symptoms (heartburn and regurgitation)
have normal endoscopic findings (non-erosive reflux
disease, or NERD), and approximately half of patients
with NERD have negative 24-hour esophageal pH
monitoring (functional heartburn) [4]. Demonstration
of the causes and consequences of disease therefore can
be challenging in these two groups of patients. Confocal
laser endomicroscopy demonstrated microstructural
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alterations of the squamous epithelium, such as an
increase in the number and diameter of intrapapillary
capillary loops and dilated intercellular spaces [5]. When
these three parameters were combined, the specificity for
a diagnosis of NERD was 100%, but the sensitivity was
only 42%. Further studies are warranted to understand
the possible clinical impact of confocal endomicroscopy
in the management of patients with NERD.
Proton pump inhibitors (PPIs) are the most effective
medical intervention for treatment of GERD [6]. However,
an incomplete response to PPIs is often reported, and there
is a clinical interest in trying to predict this response
in clinical practice. A prospective study of 100 patients
with typical GERD symptoms found that patients with
low body mass index (≤25 kg/m2), functional digestive
disorders, (irritable bowel syndrome or dyspepsia), and
the absence of esophagitis are more likely to experience
PPI failure [7]. Accordingly, Kahrilas and colleagues [8]
found that the presence of dyspepsia-like pain correlated
with a lower remission rate for heartburn. Alternative
treatments, including drugs that affect gastric motility,
tone of the lower esophageal sphincter, and esophageal
nociception, have been studied [9].
Acidic reflux has been shown to correlate with a more
proximal position of the acid pocket, which is an
unbuffered layer of acidic gastric juice above the gastric
content. A more proximal acid pocket is more common
in patients with a hiatus hernia. In a small randomized
crossover study, Rohof and collaborators [10] found that
azithromycin, a macrolide antibiotic with prokinetic
properties, reduced the size of the hiatus hernia and
lowered the position of the acid pocket, resulting in a
significant reduction in the post-prandial esophageal
acid exposure.
The primary cause of gastroesophageal reflux is transient
relaxation of the lower esophageal sphincter (LES).
Baclofen is a GABAb agonist that inhibits LES relaxation
and has a potential positive effect on both acidic and
non-acidic reflux. Since baclofen has sedating properties,
it could be particularly helpful to reduce nocturnal
reflux. In a small randomized crossover study, Orr and
colleagues [11] demonstrated that baclofen significantly
reduced the number of overnight reflux events and
improved several measures of sleep quality. The last two
studies indicate possible medical adjuncts in patients
with an incomplete response to PPIs.
Absence of acidic reflux on pH monitoring in patients
who have a positive correlation between acid reflux
events and symptoms (symptom index of greater than
50%) is defined as a hypersensitive esophagus. Patients
with hypersensitive esophagus generally have a lower
rate of response to PPI than patients with GERD, as
nociception is also triggered by non-acidic or weakly
acidic reflux. Viazis and colleagues [12] performed a
randomized controlled trial (RCT) comparing a selective
serotonin reuptake inhibitor (citalopram 20mg/day) with
placebo in 75 patients with hypersensitive esophagus. At
6 months, a significantly lower proportion of patients in
the citalopram group reported persistence of symptoms
compared with the placebo group (38.5% versus 66.7%).
This finding gives further support to the idea that at
least a proportion of GERD cases have pathophysio-
logical mechanisms in common with functional bowel
disorders.
Anti-reflux surgery is an alternative to medical therapy
and generally is indicated in patients who have
physiologically proven reflux but who do not wish to
take life-long medication or have incomplete or no
response to medical therapy [13,14]. Recently, novel
endoscopic and minimally invasive surgical procedures
have been investigated (Table 1). RCTs are warranted
before these therapeutic interventions can be recom-
mended routinely in clinical practice.
Barrett’s esophagus and esophageal
adenocarcinoma
Barrett’s esophagus (BE) is characterized by a columnar
metaplasia of the distal esophagus, which commonly
comprises an intestinal phenotype and is the only
known precursor to esophageal adenocarcinoma
(EAC). Gastroesophageal reflux is the most important
risk factor for the development of BE and EAC [15,16].
Other risk factors traditionally associated are shown in
Table 2.
The exact pathophysiological mechanisms leading to the
development of BE are not fully understood; however, it
is thought that acid-related oxidative and genotoxic
damage plays a significant role [17,18] in association
with metabolic factors and inflammatory pathways
related to the visceral adipose tissue [19].
The Hedgehog pathway, which is important during
embryonic development and stem cell function, has
been shown to have a role in BE development through
cross-talk with the underlying stroma involving epithe-
lial expression of the target gene SOX9 [20]. A Hedgehog
inhibitor was successfully used in a rat surgical model of
gastro-duodeno-esophageal reflux, in which it reduced
the incidence rate of columnar metaplasia [21]. There is
also evidence that SOX9 is directly involved in esopha-
geal carcinogenesis and can be induced by transforming
growth factor-beta (TGFb) and Notch pathways.
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Furthermore, SOX9 expression correlated with enhanced
tumor formation in a xenograft model and poor survival
in patients with EAC [22].
In addition to gene expression data, the spectrum of
somatic DNA mutations in EAC is being elucidated
through high-throughput genome sequencing methods
as part of the human genome atlas (The Cancer Genome
Atlas) [23] and the International Cancer Genome
Consortium [24]. Dulak and colleagues [25] published
the first exome (coding regions) sequencing data on 149
EACs and normal tissue pairs and identified novel genes
with recurrent mutations, including four chromatin-
modifying factors (SPG20, TLR4, DOCK2, and ELMO1,
the latter of which has been shown to be involved in cell
invasion).
BE is generally thought to be a consequence of life-style
and environmental factors, although familial clustering
is reported in about 7% of individuals with BE or EAC
[26]. In 2012, the first genome-wide association study
(GWAS), based on 1,852 UK cases of BE and 5,172
controls, was published (Table 1). Two variants on
chromosome 6p21 and 16q24 were associated with BE
compared with controls [27], and their association with
esophageal cancer was validated in an independent
Dutch case-control study [28]. Other GWASs are
currently being performed and hopefully will provide
new insight into the genetic predisposition to cancer
progression in BE.
The rate of progression from BE to cancer has been the
focus of several publications. A recent meta-analysis and
two population studies found that the cancer risk in BE is
lower than previously thought (around 0.3% per year)
[29-31]). Furthermore, a retrospective community-based
case-control study in a population of 8,272 patients with
BE found that, among the 70 EAC cases with a previous
diagnosis of BE, surveillance within 3 years was not
associated with a decreased risk of cancer-related death
[32]. Despite the limitations of this study, including the
small number of cases and the unusually high prevalence
of advanced-stage disease (50%) in EAC cases with
known BE, this study adds to the controversial debate
surrounding the usefulness of surveillance in BE. The
major limitation of endoscopic surveillance is that
dysplasia and early neoplasia are often invisible at
endoscopy and therefore can be missed by random
sampling. Increased molecular knowledge of BE patho-
genesis has allowed investigators to devise molecular
imaging algorithms, which aim to enhance detection of
pre-neoplastic lesions. For example, a fluorescently
labeled lectin (wheat germ agglutinin), which differen-
tially binds surface glycoprotein of dysplastic and
normal cells, has been shown in proof of principle to
localize areas of inconspicuous dysplasia in surgically
resected esophagi [33]. Similarly, a different group of
investigators identified a fluorescent peptide with high
affinity for neoplastic cells, which, in combination with
confocal laser endomicroscopy, could be used to image
early EAC. Further in vivo data are required to determine
the usefulness of this approach in routine endoscopic
surveillance [34].
The limitation of surveillance strategies, together with
the dramatic increase in the incidence of EAC seen over
Table 1. Novel endoscopic and minimally invasive procedures for the management of gastroesophageal reflux disease
Technique Methodology Design Number of
patients
Results Comments Reference
Stretta Endoscopic delivery
of radiofrequency
energy to the LES
Meta-analysis 1,441 Improvement of
heartburn (P = 0.001),
QoL (P = 0.001), and
esophageal pH
(P = 0.007)
Unclear
pathophysiological
mechanism.
Heterogeneous results
[84]
Implanted
electrical
stimulator
Increase LES
pressure by
electrical
stimulation
Cohort with
6-month
follow-up
24 Improvement of symptom
score (P < 0.001) and
esophageal pH (P < 0.001)
Small study. Short
follow-up. Laparoscopic
implant required
[85]
LINX™ Sphincter
augmentation by
ring of magnetic
beads
Cohort with
5-year follow-up
100 At least 50% reduction in
esophageal pH in 64% of
patients (P < 0.001). At
least 50% improvement
in QoL scores in 92%
of patients
Dysphagia in 68% of
patients post-op (11%
and 4% at 1 and
3 years). Serious
adverse events in 6%
[86]
Esophyx Transoral
incisionless
fundoplication
Cohort with
24-month
follow-up
42 77% and 70% of patients
stopped or reduced PPI
at 6 and 24 months,
respectively
Low efficacy in cases
with large hiatus hernia
and ineffective motility
[87]
LES, lower esophageal sphincter; LINX; PPI, proton pump inhibitor; QoL, quality of life.
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the last 30 years, underscores the need to find better ways
to identify patients at high risk for progression and to
intervene at an early stage [35]. Clinico-pathological
factors are limited in their ability to predict BE behavior.
Low-grade dysplasia (LGD), despite the high inter-
observer variability among pathologists [36,37], and
the length of BE are the only clinical parameters that have
consistently been associated with cancer risk [38]. To
overcome the paucity of clinical parameters for risk
stratification, research has focused on the use of
biomarkers [39]. A Dutch case-control study on a
prospective cohort of 720 patients with BE found that
aberrant p53 expression detected by immunohisto-
chemistry confers a relative risk for neoplastic progres-
sion of 5.6 (95% confidence interval [CI] 3.1-10.3) [40].
A nested case-control study (89 cases of BE that progressed
to high-grade dysplasia [HGD] or cancer and 291 non-
progressors) found that a small biomarker panel
comprising LGD, aneuploidy, and expression of the
Aspergillus oryzae lectin predicts progression with an
odds ratio (OR) of 2.99 (95% CI 1.72-5.20) for each
abnormal biomarker. One of the outstanding challenges
in BE is that the majority of cases are undiagnosed and
hence the majority of patients with EAC present de novo.
Endoscopic screening on a population basis is not
feasible and less invasive modalities have been investi-
gated. One of them couples a cytology collection device,
Cytosponge™, with an immunochemical marker, trefoil
factor 3 (TFF3), which is highly specific for cells with an
intestinal phenotype. This test was devised by the
Medical Research Council UK for the purpose of clinical
trials [41]. This test is feasible in the primary care setting
and has a diagnostic accuracy for BE comparable to other
screening tests such as fecal occult blood (FOB) and
cervical Papanicolaou smears. In a microsimulation
model, screening 50-year-old men with GERD
Table 2. Risk factors associated with Barrett’s esophagus, esophageal adenocarcinoma, and esophageal squamous cell carcinoma in
recent studies
Risk factor Disease Methods Number of patients Effect size Reference
Obesity
(waist-to-hip ratio)
BE and EAC Case-control 225 cases 675 controls OR (highest versus lowest
quartile): 2.68 (95% CI
1.57-4.55)
[88]
Heartburn BE Cross-sectional 1,058 cases with GERD OR 1.5, 95% CI 1.07-2.09 [89]
Caucasian race OR 2.4, 95% CI 1.42-4.03
Hiatus hernia OR 2.07, 95% CI 1.5-2.87
Weekly GERD BE Cross-sectional 822 males undergoing
screening colonoscopy
OR 2.33, 95% CI 1.34-4.35 [90]
Obesity
(waist-to-hip ratio)
OR per 0.10: 1.44; 95% CI
0.9-2.32
Age OR per 10 years: 1.53; 95%
CI 1.05-2.25
Smoking OR per 10 pack-years: 1.09;
95% CI 1.04-1.14
HPV BE dysplasia and EAC Retrospective
case-control
261 patients with BE IRR for dysplasia: 2.94; 95%
CI 1.78-4.85 IRR for EAC:
2.87; 95% CI 1.69-4.86
[91]
ESCC Retrospective
case-control
300 cases 900 controls OR 6.4, 95% CI 4.4-9.2 [92]
Genomic variants
rs9936833
BE (C allele) GWAS 1,852 BE cases and 5,172
controls
OR 1.14, 95% CI 1.10-1.17 [27]
EAC (C allele) Case control 431 BE cases and 605
controls
OR 1.21, 95% CI 0.99-1.47 [28]
Genomic variant
rs9257809
BE (A allele) GWAS 1,852 BE cases and 5,172
controls
OR 1.21, 95% CI 1.13-1.28 [27]
ESCC (G allele) Case control 431 BE cases and 605
controls
OR 1.76, 95% CI 1.16-2.66 [28]
Heavy alcohol con-
sumption (>30gr/day)
ESCC Cohort 120,852 participants (107
ESCC cases)
IRR 4.61, 95% CI 2.24-9.50 [93]
Light alcohol con-
sumption (≤1 drink/
day)
ESCC Meta-analysis ~92,000 light drinkers and
~60,000 non-drinkers
RR 1.3, 95% CI 1.09-1.56 [29]
Smoking (current) ESCC Cohort 120,852 participants (107
ESCC cases)
RR 2.63 [93]
Processed meat
consumption
ESCC Cohort 120,852 participants (107
ESCC cases)
HR 3.47 (95% CI 1.21-9.94) [95]
High variety in fruit
and vegetable
consumption
ESCC Cohort 452,269 participants (98
ESCC cases)
HR 0.88 (95% CI 0.79-0.97) [96]
BE, Barrett’s esophagus; CI, confidence interval; EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; GERD, gastroesophageal reflux
disease; GWAS, genome-wide association study; HPV, human papilloma virus; HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, relative risk.
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symptoms with Cytosponge™ reduced mortality from
EAC compared with no screening and was cost-effective
compared with endoscopic screening [42]. Alternatively,
a tethered capsule endomicroscopy has been devised to
scan the upper gastrointestinal tract and provide three-
dimensional reconstruction and microstructural images
of the esophageal mucosa [43]. This uses optical
frequency domain imaging, which is based on reflection
of infrared light. Following the pilot study in six patients,
large prospective studies are needed to confirm that this
device has good acceptability and accuracy for screening
for BE.
In the last 5 to 10 years, the biggest advance in the
management of BE and early EAC has been the advent of
endoscopic therapy. This generally comprises endoscopic
resection (ER) for early neoplasia and ablative techni-
ques for the eradication of inconspicuous dysplasia.
Currently, radiofrequency ablation (RFA) is the ablative
technique with the best safety and efficacy profile [44].
Endoscopic treatment has allowed patients with HGD or
early cancer to be shifted away from the surgical pathway
[45]. Data from a large UK registry including 335 patients
with HGD or intramucosal cancer treated with RFA in
combination with ER if required, showed a 12-month
eradication rate for neoplasia of 86% and a rate of
complete eradication of intestinal metaplasia of 62%
[46]. Even though these efficacy data are lower than
those reported in well-controlled prospective series
[47,48], they represent outcomes from real-life clinical
scenarios and therefore indicate that this new therapeutic
paradigm is feasible and effective in routine practice.
However, it is clear that continued endoscopic follow-up
of these patients is required as some patients will need
further endoscopic or surgical therapy for persistent or
recurrent disease. An expert consensus review in 2012
recommended endoscopic therapy over surgery for the
treatment of HGD and T1m esophageal and junctional
adenocarcinoma [49].
On the other hand, most patients with EAC present with
advanced disease requiring neoadjuvant oncological
therapy followed by surgery. There are intensive treat-
ment regimens associated with significant morbidity and
mortality, particularly in older patients with coexisting
medical problems. Therefore, better predictors of out-
come than radiological estimates of pre-treatment are
required to help patients and clinicians make manage-
ment decisions. In patients with established EAC, a
panel of three immunohistochemical markers – EGFR,
TRIM44, and SIRT2 – can split patients with EAC into
two prognostic groups, which are independent of clinical
stage, with a hazard ratio for adverse survival of 1.2
(95% CI 1.03 to 1.4) for each positive biomarker [50].
Squamous dysplasia and squamous cell
carcinoma
From a global perspective, esophageal squamous cell
carcinoma (ESCC) is still the most common esophageal
malignancy [51]. Risk factors recently associated with
ESCC are listed in Table 1. A recent GWAS on over 2,000
cases and 2,000 controls found nine new susceptibility
loci for ESCC, of which two showed significant interac-
tion with alcohol drinking, suggesting that the etiology
of this cancer is multifactorial and that multiple genes
interact with strong environmental risk factors [52].
Two recent studies have investigated prognostic factors in
ESCC. A GWAS found that a single-nucleotide poly-
morphism in a gene coding for a zinc transporter
(SLC39A6) is associated with worse survival with a
hazard ratio for death of 1.3 (95% CI 1.19-1.43) [53].
Another predictor of clinical disease behavior is p53
expression, and a meta-analysis of 28 studies found that
normal p53 expression or maintenance of wild-type p53
gene correlated with high response to chemotherapy-
based treatments and a high rate of complete patholo-
gical response to neo-adjuvant chemoradiotherapy [54].
Two additional ESCC tumor markers have recently been
identified. The protein tyrosine kinase 6 (PTK6) is
epigenetically downregulated in ESCC and its tumor
suppressor function was validated by proliferation and
migration in in vitro assays and in a xenograft model [55].
In another study, a lipid raft protein, FLOT1, was found
to be overexpressed in ESCC cell lines and tissue
samples, where it acts as a promoter of proliferation
and cell motility and an inhibitor of apoptosis [56].
Future work will be required to establish whether these
markers can be used clinically to predict disease behavior
or target molecular therapy in the clinic.
Similarly to EAC, early diagnosis of ESCC is important
not only because it ensures higher survival rates
compared with standard therapeutic interventions
(chemo-radiotherapy with or without surgery) but also
because it opens the possibility to offer patients
minimally invasive endoscopic treatment. A large retro-
spective cohort study of 570 patients with early ESCC
treated with endoscopic resection showed a 90% 5-year
survival rate in patients with disease confined within the
lamina propria (LPM); however, the survival rate
dropped to 70% when muscularis mucosae (MM) or
the submucosa (SM) was involved [57]. In keeping with
this, the cumulative 5-year metastasis rate in patients
with LPM, MM, SM1, and SM2 disease were 0.4, 8.7, 7.7,
and 36%, respectively. This highlights a fundamental
difference between early EAC and early ESCC, whereby
involvement of MM is compatible with endoscopic
therapy in EAC but not in ESCC. However, squamous
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dysplasia is often inconspicuous at endoscopy; therefore,
advanced imaging modalities are needed to flag suspi-
cious areas. One of these is chromoendoscopy using
Lugol’s iodine, which exploits the lower affinity of iodine
to dysplastic compared to normal epithelium [58]. An
alternative way to image dysplastic tissue is molecular
imaging. Periostin is an adhesion molecule highly
expressed in the ESCC tumor microenvironment. Wong
and colleagues [59] used a fluorescently labelled anti-
body against periostin in combination with near-
infrared endoscopy to image esophageal neoplasia in a
cancer mouse model that resembles ESCC.
Eosinophilic esophagitis
EoE is a relatively recently described clinico-pathological
entity characterized by symptoms of esophageal dysfunc-
tion and microscopic esophageal eosinophilia (>15
eosinophils/high-power field), which persists after a
2-month course of PPI and when other causes of
eosinophilia have been excluded. The American guide-
lines for the management of EoE were recently issued
[60]. Patients with EoE may have one of more of the
following endoscopic findings – rings, strictures, narrow
caliber, furrows, plaques, or mucosal pallor – and up to
93% may have at least one of these features in
prospective studies. However, the overall diagnostic
accuracy based on the endoscopic appearance is poor;
sensitivity ranges between 15% and 48%; therefore,
histological corroboration is mandatory [61]. However,
it is often challenging to distinguish between EoE and
GERD. First, they can present with similar symptoms,
second, mucosal eosinophilia is a common finding in
GERD, and finally, patients with negative pHmonitoring
and symptoms and histological findings suggestive of
EoE can have symptomatic and histological resolution
when treated with a PPI. This has been confirmed by a
recent RCT in which patients with symptoms of
esophageal dysfunction and esophageal eosinophilia
were randomly assigned to either topical fluticasone
440 mg twice daily or esomeprazole 40 mg once daily
[62]. Although PPI treatment correlated with a better
symptomatic response (dysphagia score) compared with
topical steroid among patients who had normal pH
monitoring, there was no statistical difference in the
histologic response, and a resolution of eosinophilia
was seen in 33% and 19% of patients, respectively.
Another RCT showed better rates of symptomatic and
histologic response (68% and 63%, respectively) with
higher doses of topic fluticasone (880 mg twice daily);
however, esophageal candidiasis occurred in about a
quarter of cases [63]. To help distinguish between
EoE and GERD, tissue biomarkers have been studied.
A recent case-control study tested four immunohisto-
chemistry markers and found that the combination of
major basic protein (MBP) and eotaxin-3 together with
the eosinophil count had an area under curve for a
diagnosis of EoE of 0.99 [64]. Improved understanding
of the pathogenesis of EoE has led to development of
new alternative treatment to steroids and PPI [65]. EoE
is triggered by a Th2 allergic reaction to food, which
involves release of eotaxin-3 and interleukins (IL) 5 and
13 that, in turn, induces eosinophil trafficking in the
esophagus. Promising results have recently been
obtained with treatment of pediatric and adult EoE
patients with a six-food elimination diet (SFED) (milk,
soy, nuts, fish, eggs, and wheat) for 6 weeks followed by
progressive reintroduction every 2 weeks, while mon-
itoring histologic and symptom scores. In a prospective
cohort of 50 patients, SFED led to a complete histologic
response in 64% of patients, and up to 78% showed at
least 50% reduction in the eosinophil count, and there
was a symptomatic response in 94% of patients [66].
When foods were reintroduced, the most common
relapse triggers were wheat (60% of cases) and milk
(50% of cases). Similar results were found in another
cohort study with long-term follow-up, where remission
of symptoms could be maintained for up to 3 years
[67]. Of note, both studies showed that conventional
allergy tests (serum IgE and skin prick test) have limited
value with low sensitivity values. On the downside, the
SFED is a lengthy process and the rate of compliance to
the reintroduction process in clinical practice may be even
lower outside research protocols. However, the advantage
compared with other dietary interventions, such as
elemental diet, is the improved quality of life, although
comparative studies are lacking. Of note, elemental diet,
which was shown to be very effective in pediatric patients
[68], did not improve symptoms of EoE in a small adult
cohort despite improving histological scores [69].
Biological agents are currently being tested with the
intent of blocking the molecular cascade responsible for
the allergenic process. A large RCT that compared three
different doses of an anti-IL-5 antibody (reslizumab)
with placebo in a pediatric cohort showed improvement
of the histologic score in all treatment groups; however,
significant symptomatic benefit was lacking [70]. Similar
results were obtained with a different anti-IL-5 antibody
in a small cohort study [71].
Esophageal motility disorders
Esophageal motility disorders are the most common
cause of esophageal symptoms after GERD. They
classically include achalasia, diffuse esophageal spasm
(DES), hypertensive lower esophageal sphincter (LES),
and nutcracker esophagus (NE). The advent of high-
resolution esophageal pressure topography has
enhanced the characterization of these conditions and,
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in 2008, the Chicago Classification was developed to
refine the diagnostic criteria. A recent iteration of this
classification was published in 2012 [72]. The main
innovations of the Chicago Classification are the
subclassification of achalasia into three types, which
impacts on clinical management, and the introduction of
two additional diagnoses: esophagogastric outflow
obstruction and hypercontractile esophagus [73]. Tsutsui
and colleagues [74] looked at the association of globus
with motility disorders. Globus is one of the atypical
symptoms of GERD but frequently fails to respond to
PPI. The authors found that, among 119 patients with
globus non-responsive to PPI, abnormal esophageal
motility was found in nearly 50% of cases [74]. About 2
out of 3 had ineffective esophageal motility and 1 out of
3 was equally divided among achalasia, NE, and DES.
Whereas the therapeutic algorithm for achalasia is well
defined, treatment of other conditions remains challen-
ging, and medical therapy often proves disappointing
and surgery helpful only in well-selected groups [75].
In a small RCT with a crossover design that included
22 patients with NE andDES, Botox (Allergan, Inc., Irvine,
CA, USA) injection 2 and 7 cm above the esophago-
gastric junction (EGJ) was beneficial compared with
placebo; however, only 30% of patients maintained
response at 1 year [76]. Similarly, results of Botox
injection in patients with achalasia are short-lived; there
is almost universal recurrence at 2 years [75]. An
alternative endoscopic treatment for achalasia is pneu-
matic dilatation (PD), which mechanically and perma-
nently disrupts muscle fibers. A recent retrospective series
of 301 patients undergoing PD showed an 82%
remission rate at 1 year but a 2% perforation rate [77].
Kaplan-Meier analysis, in which symptomatic relapse
after first PD and need of additional therapy (PD or
other) were considered as treatment failures, demon-
strated that 59% and 40% of the patients maintain
remission at 5 and 10 years, respectively. A meta-analysis
of 36 studies compared outcomes of PD and surgical
myotomy and found that surgery guarantees longer rates
of remission (76% and 79% at 5 and 10 years,
respectively) but with a perforation rate that was twice
that of PD [78]. Probably the most exciting advance in
the management of patients with motility disorders is
the recent introduction of a novel minimally invasive
endoscopic technique, called per-oral esophageal myot-
omy (POEM). This involves the creation of a submucosal
tunnel with an ESD approach from the mid esophagus
until beyond the EGJ, division of the inner muscle layer
with an endoscopic knife and closure of the mucosal
entry with clips. POEM was first performed in Japan in
2008 by Haruhiro Inoue, and several hundred cases have
been completed in Eastern andWestern countries. Recent
case series confirmed that POEM is effective in both
relieving symptoms and improving esophageal physiol-
ogy [79-81], regardless of whether the patients received
endoscopic therapy. A multicenter study of 70 patients
showed symptomatic remission at 6 and 12 months in
89% and 82% of patients, respectively, and a significant
reduction of the mean lower esophageal pressure from
28 to 9 mm Hg [82]. A non-randomized cohort study
compared the perioperative outcomes of POEM and
Heller’s myotomy and found that complication rate,
length of stay, and pain scores were similar between the
two techniques, although POEM had shorter operative
time and lower estimated blood loss [83]. Longer
follow-up data are needed to determine the long-term
benefit of this technique.
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